Clinical Development of 2B1 Bispecific Monoclonal AB

Weiner, Louis M.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 5U01CA058262-04
• Application #: 2098962
• Study Section: Special Emphasis Panel (SRC (59))
• Project Start: 1993-09-10
• Project End: 1997-06-30
• Budget Start: 1996-07-01
• Budget End: 1997-06-30
• Support Year: 4
• Fiscal Year: 1996

Institution

• Name: Fox Chase Cancer Center
• DUNS #: 042250712
• City: Philadelphia
• State: PA
• Country: United States
• Zip Code: 19111

Publications

Borghaei, Hossein; Alpaugh, R Katherine; Bernardo, Patricia et al. (2007) Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. J Immunother 30:455-67

Weiner, L M; Alpaugh, R K; von Mehren, M (1997) Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins. Cancer Immunol Immunother 45:190-2

Weiner, L M; Clark, J I; Ring, D B et al. (1995) Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 4:453-6